“减肥神药”，价格大跳水

Core Insights - The recent price reductions of GLP-1 drugs, particularly Novo Nordisk's semaglutide (brand name: Ozempic) and Eli Lilly's dual-target drug tirzepatide (brand name: Mounjaro), have garnered significant attention due to their popularity as weight loss medications [1] Pricing Adjustments - Novo Nordisk's semaglutide injection prices have been significantly reduced, with the 2.27mg/mL×3mL specification dropping from 1893.67 yuan to 987.48 yuan, and the 3.2mg/mL×3mL specification from 2463 yuan to 1284.36 yuan, representing nearly a 50% decrease [2] - The price of Mounjaro has also been adjusted, with various specifications seeing reductions of approximately 80%, such as the 10mg specification dropping from 1758 yuan to 324.12 yuan [3] Cost Savings for Patients - Prior to the price reduction, patients using Mounjaro for weight loss would incur costs exceeding 13,000 yuan over 16 weeks, but post-reduction, this cost has decreased to around 2,500 yuan, resulting in savings of over 10,000 yuan [3] E-commerce Price Trends - E-commerce platforms are also reflecting price reductions, with Mounjaro priced at 439 yuan for the 10mg specification on Meituan's platform, attributed to official subsidies [4][6] Future Market Dynamics - The anticipated expiration of Novo Nordisk's patent for semaglutide in 2026 is expected to lead to an influx of generic drugs and increased competition, potentially driving prices lower [8] - The production costs of GLP-1 drugs may align with those of insulin, suggesting that future pricing could be competitive, although the final pricing will depend on various market factors [9]